Business Description
DMK Pharmaceuticals Corp
NAICS : 325412
SIC : 2834
ISIN : US00547W2089
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 105.78 | |||||
Equity-to-Asset | -0.59 | |||||
Debt-to-Equity | -0.01 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -58.65 | |||||
Beneish M-Score | 6.07 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -57.6 | |||||
3-Year EBITDA Growth Rate | 30 | |||||
3-Year EPS without NRI Growth Rate | 31.5 | |||||
3-Year FCF Growth Rate | 25.4 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
14-Day RSI | 41.15 | |||||
12-1 Month Momentum % | -80.41 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.58 | |||||
Quick Ratio | 0.54 | |||||
Cash Ratio | 0.5 | |||||
Days Inventory | 63.49 | |||||
Days Sales Outstanding | 119.03 | |||||
Days Payable | 651.62 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -34.4 | |||||
Shareholder Yield % | 162.71 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | -37.27 | |||||
Operating Margin % | -519.31 | |||||
Net Margin % | -614.17 | |||||
FCF Margin % | -259.91 | |||||
ROA % | -242.45 | |||||
ROIC % | -520.22 | |||||
ROC (Joel Greenblatt) % | -998.33 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.03 | |||||
EV-to-Revenue | 0.01 | |||||
EV-to-Forward-Revenue | 1.74 | |||||
FCF Yield % | -1874.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
DMK Pharmaceuticals Corp Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 3.402 | ||
EPS (TTM) (€) | -8.928 | ||
Beta | 0 | ||
Volatility % | 110.44 | ||
14-Day RSI | 41.15 | ||
14-Day ATR (€) | 0.000007 | ||
20-Day SMA (€) | 3.444 | ||
12-1 Month Momentum % | -80.41 | ||
52-Week Range (€) | 3.121999 - 25.374999 | ||
Shares Outstanding (Mil) | 10.09 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
DMK Pharmaceuticals Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
DMK Pharmaceuticals Corp Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
DMK Pharmaceuticals Corp Frequently Asked Questions
What is DMK Pharmaceuticals Corp(FRA:CY3)'s stock price today?
When is next earnings date of DMK Pharmaceuticals Corp(FRA:CY3)?
Does DMK Pharmaceuticals Corp(FRA:CY3) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |